24/7 Market News Snapshot 13 November, 2024 – Calidi Biotherapeutics, Inc. (NYSE:CLDI)

November 13, 2024

DENVER, Colo., 13 November, 2024 (247marketnews.com) – (NYSE:CLDI) are discussed in this article.
Calidi Biotherapeutics, Inc. has demonstrated significant momentum in the market, opening at $2.50 and experiencing a remarkable surge of 27.54% to reach a trading price of $2.69. This increase is underscored by an impressive trading volume of 22.70 million shares, highlighting robust investor interest and confidence in the company’s future. Such bullish activity positions Calidi as a notable player within the biotherapeutics sector, where it focuses on pioneering innovations in cancer treatment.

In a strategic move to bolster its operational capabilities, Calidi has announced plans for a public offering of its common stock, which may also include pre-funded warrants. This offering, which will be solely conducted by the company with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent, aims to secure funds for working capital and general corporate purposes. The exact size and terms of the offering remain to be finalized, contingent upon market conditions, and will be executed under the shelf registration statement filed with the U.S. Securities and Exchange Commission.

Calidi Biotherapeutics is committed to transforming oncology treatment through its proprietary technology that leverages allogeneic stem cells to deliver oncolytic viruses targeting high-grade gliomas and other solid tumors. The company’s innovative, off-the-shelf, cell-based platform is designed to enhance treatment effectiveness while prioritizing patient safety.

As this public offering progresses, Calidi encourages stakeholders and investors to stay informed through upcoming updates and preliminary prospectuses, further illustrating its dedication to addressing critical unmet needs in cancer therapy and fostering advancements in immuno-oncology. With an unwavering commitment to improving patient outcomes, Calidi positions itself as a key contender in the evolving landscape of cancer treatment solutions.

Related news for (CLDI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.